Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNF472 for cardiovascular calcification in ESRD patients on hemodialysis
NCT02966028Phase 2Completed
- Sponsor
- Sanifit Therapeutics
- Start
- Nov 2016
- Primary completion
- Aug 2019
- Modality
- Peptides, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of SNF472 in Coronary artery calcification (CAC), sponsored by Sanifit Therapeutics. Started Nov 2016; status: completed.
02
Drugs
SNF472
03
Conditions
Coronary artery calcification (CAC)
Beyond the preview
Go deeper on NCT02966028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966028.